Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atropine Dose-Ranging with Pseudoephedrine and Chlorpheniramine in SAR
NCT02082054Phase 2Unknown
- Sponsor
- Magna Pharmaceuticals
- Start
- Mar 2014
- Primary completion
- May 2014
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of atropine in seasonal allergic rhinitis (SAR) (5 arms), sponsored by Magna Pharmaceuticals. Primary endpoint: Total Nasal Symptom Score at 7.5 days. Status: unknown.
02
Drugs
atropine
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on NCT02082054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02082054.